Global Tumour Neoantigens Market Growth 2022-2028
The report requires updating with new data and is sent in 48 hours after order is placed.
Tumor neoantigens, as their name implies, are antigens that are not expressed in normal tissues but are expressed only in tumor tissues, including those produced by the integration of oncogenic viruses into the genome and mutant proteins, and neoantigens are not only highly specific but also strongly immunogenic because of their unselected thymus negative screening.
The global market for Tumour Neoantigens is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Tumour Neoantigens market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Tumour Neoantigens market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Tumour Neoantigens market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Tumour Neoantigens market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Tumour Neoantigens players cover Achilles Therapeutics plc, Advaxis Immunotherapies, Genocea, Gradalis, Inc and Gritstone bio, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Tumour Neoantigens market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Tumour Neoantigens market, with both quantitative and qualitative data, to help readers understand how the Tumour Neoantigens market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Tumour Neoantigens market and forecasts the market size by Type (Common Neoantigens and Individualized Neoantigens,), by Application (T Cell Adoptive Therapy, DC Therapy, Therapeutic Vaccines and Other), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
Chapter 1: Scope of Tumour Neoantigens, Research Methodology, etc.
Chapter 2: Executive Summary, global Tumour Neoantigens market size (sales and revenue) and CAGR, Tumour Neoantigens market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Tumour Neoantigens sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Tumour Neoantigens sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Tumour Neoantigens market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Achilles Therapeutics plc, Advaxis Immunotherapies, Genocea, Gradalis, Inc, Gritstone bio, Iovance Biotherapetics Inc, Medigene AG, BioNTech SE and Lilly, etc.
Chapter 14: Research Findings and Conclusion
Tumor neoantigens, as their name implies, are antigens that are not expressed in normal tissues but are expressed only in tumor tissues, including those produced by the integration of oncogenic viruses into the genome and mutant proteins, and neoantigens are not only highly specific but also strongly immunogenic because of their unselected thymus negative screening.
The global market for Tumour Neoantigens is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
The APAC Tumour Neoantigens market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The United States Tumour Neoantigens market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The Europe Tumour Neoantigens market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
The China Tumour Neoantigens market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.
Global key Tumour Neoantigens players cover Achilles Therapeutics plc, Advaxis Immunotherapies, Genocea, Gradalis, Inc and Gritstone bio, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
Report Coverage
This latest report provides a deep insight into the global Tumour Neoantigens market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.
This report aims to provide a comprehensive picture of the global Tumour Neoantigens market, with both quantitative and qualitative data, to help readers understand how the Tumour Neoantigens market scenario changed across the globe during the pandemic and Russia-Ukraine War.
The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.
Market Segmentation:
The study segments the Tumour Neoantigens market and forecasts the market size by Type (Common Neoantigens and Individualized Neoantigens,), by Application (T Cell Adoptive Therapy, DC Therapy, Therapeutic Vaccines and Other), and region (APAC, Americas, Europe, and Middle East & Africa).
Segmentation by type
- Common Neoantigens
- Individualized Neoantigens
- T Cell Adoptive Therapy
- DC Therapy
- Therapeutic Vaccines
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Achilles Therapeutics plc
- Advaxis Immunotherapies
- Genocea
- Gradalis, Inc
- Gritstone bio
- Iovance Biotherapetics Inc
- Medigene AG
- BioNTech SE
- Lilly
- Scicomvisuals
- Moderna, Inc
- F. Hoffmann-La Roche Ltd
- Merck KGaA
- Sun Pharmaceutical Industries Ltd
Chapter 1: Scope of Tumour Neoantigens, Research Methodology, etc.
Chapter 2: Executive Summary, global Tumour Neoantigens market size (sales and revenue) and CAGR, Tumour Neoantigens market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Tumour Neoantigens sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Tumour Neoantigens sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Tumour Neoantigens market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Achilles Therapeutics plc, Advaxis Immunotherapies, Genocea, Gradalis, Inc, Gritstone bio, Iovance Biotherapetics Inc, Medigene AG, BioNTech SE and Lilly, etc.
Chapter 14: Research Findings and Conclusion
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Tumour Neoantigens Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Tumour Neoantigens by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Tumour Neoantigens by Country/Region, 2017, 2022 & 2028
2.2 Tumour Neoantigens Segment by Type
2.2.1 Common Neoantigens
2.2.2 Individualized Neoantigens
2.3 Tumour Neoantigens Sales by Type
2.3.1 Global Tumour Neoantigens Sales Market Share by Type (2017-2022)
2.3.2 Global Tumour Neoantigens Revenue and Market Share by Type (2017-2022)
2.3.3 Global Tumour Neoantigens Sale Price by Type (2017-2022)
2.4 Tumour Neoantigens Segment by Application
2.4.1 T Cell Adoptive Therapy
2.4.2 DC Therapy
2.4.3 Therapeutic Vaccines
2.4.4 Other
2.5 Tumour Neoantigens Sales by Application
2.5.1 Global Tumour Neoantigens Sale Market Share by Application (2017-2022)
2.5.2 Global Tumour Neoantigens Revenue and Market Share by Application (2017-2022)
2.5.3 Global Tumour Neoantigens Sale Price by Application (2017-2022)
3 GLOBAL TUMOUR NEOANTIGENS BY COMPANY
3.1 Global Tumour Neoantigens Breakdown Data by Company
3.1.1 Global Tumour Neoantigens Annual Sales by Company (2020-2022)
3.1.2 Global Tumour Neoantigens Sales Market Share by Company (2020-2022)
3.2 Global Tumour Neoantigens Annual Revenue by Company (2020-2022)
3.2.1 Global Tumour Neoantigens Revenue by Company (2020-2022)
3.2.2 Global Tumour Neoantigens Revenue Market Share by Company (2020-2022)
3.3 Global Tumour Neoantigens Sale Price by Company
3.4 Key Manufacturers Tumour Neoantigens Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Tumour Neoantigens Product Location Distribution
3.4.2 Players Tumour Neoantigens Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR TUMOUR NEOANTIGENS BY GEOGRAPHIC REGION
4.1 World Historic Tumour Neoantigens Market Size by Geographic Region (2017-2022)
4.1.1 Global Tumour Neoantigens Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Tumour Neoantigens Annual Revenue by Geographic Region
4.2 World Historic Tumour Neoantigens Market Size by Country/Region (2017-2022)
4.2.1 Global Tumour Neoantigens Annual Sales by Country/Region (2017-2022)
4.2.2 Global Tumour Neoantigens Annual Revenue by Country/Region
4.3 Americas Tumour Neoantigens Sales Growth
4.4 APAC Tumour Neoantigens Sales Growth
4.5 Europe Tumour Neoantigens Sales Growth
4.6 Middle East & Africa Tumour Neoantigens Sales Growth
5 AMERICAS
5.1 Americas Tumour Neoantigens Sales by Country
5.1.1 Americas Tumour Neoantigens Sales by Country (2017-2022)
5.1.2 Americas Tumour Neoantigens Revenue by Country (2017-2022)
5.2 Americas Tumour Neoantigens Sales by Type
5.3 Americas Tumour Neoantigens Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tumour Neoantigens Sales by Region
6.1.1 APAC Tumour Neoantigens Sales by Region (2017-2022)
6.1.2 APAC Tumour Neoantigens Revenue by Region (2017-2022)
6.2 APAC Tumour Neoantigens Sales by Type
6.3 APAC Tumour Neoantigens Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Tumour Neoantigens by Country
7.1.1 Europe Tumour Neoantigens Sales by Country (2017-2022)
7.1.2 Europe Tumour Neoantigens Revenue by Country (2017-2022)
7.2 Europe Tumour Neoantigens Sales by Type
7.3 Europe Tumour Neoantigens Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Tumour Neoantigens by Country
8.1.1 Middle East & Africa Tumour Neoantigens Sales by Country (2017-2022)
8.1.2 Middle East & Africa Tumour Neoantigens Revenue by Country (2017-2022)
8.2 Middle East & Africa Tumour Neoantigens Sales by Type
8.3 Middle East & Africa Tumour Neoantigens Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Tumour Neoantigens
10.3 Manufacturing Process Analysis of Tumour Neoantigens
10.4 Industry Chain Structure of Tumour Neoantigens
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Tumour Neoantigens Distributors
11.3 Tumour Neoantigens Customer
12 WORLD FORECAST REVIEW FOR TUMOUR NEOANTIGENS BY GEOGRAPHIC REGION
12.1 Global Tumour Neoantigens Market Size Forecast by Region
12.1.1 Global Tumour Neoantigens Forecast by Region (2023-2028)
12.1.2 Global Tumour Neoantigens Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Tumour Neoantigens Forecast by Type
12.7 Global Tumour Neoantigens Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Achilles Therapeutics plc
13.1.1 Achilles Therapeutics plc Company Information
13.1.2 Achilles Therapeutics plc Tumour Neoantigens Product Offered
13.1.3 Achilles Therapeutics plc Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Achilles Therapeutics plc Main Business Overview
13.1.5 Achilles Therapeutics plc Latest Developments
13.2 Advaxis Immunotherapies
13.2.1 Advaxis Immunotherapies Company Information
13.2.2 Advaxis Immunotherapies Tumour Neoantigens Product Offered
13.2.3 Advaxis Immunotherapies Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Advaxis Immunotherapies Main Business Overview
13.2.5 Advaxis Immunotherapies Latest Developments
13.3 Genocea
13.3.1 Genocea Company Information
13.3.2 Genocea Tumour Neoantigens Product Offered
13.3.3 Genocea Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Genocea Main Business Overview
13.3.5 Genocea Latest Developments
13.4 Gradalis, Inc
13.4.1 Gradalis, Inc Company Information
13.4.2 Gradalis, Inc Tumour Neoantigens Product Offered
13.4.3 Gradalis, Inc Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Gradalis, Inc Main Business Overview
13.4.5 Gradalis, Inc Latest Developments
13.5 Gritstone bio
13.5.1 Gritstone bio Company Information
13.5.2 Gritstone bio Tumour Neoantigens Product Offered
13.5.3 Gritstone bio Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Gritstone bio Main Business Overview
13.5.5 Gritstone bio Latest Developments
13.6 Iovance Biotherapetics Inc
13.6.1 Iovance Biotherapetics Inc Company Information
13.6.2 Iovance Biotherapetics Inc Tumour Neoantigens Product Offered
13.6.3 Iovance Biotherapetics Inc Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Iovance Biotherapetics Inc Main Business Overview
13.6.5 Iovance Biotherapetics Inc Latest Developments
13.7 Medigene AG
13.7.1 Medigene AG Company Information
13.7.2 Medigene AG Tumour Neoantigens Product Offered
13.7.3 Medigene AG Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Medigene AG Main Business Overview
13.7.5 Medigene AG Latest Developments
13.8 BioNTech SE
13.8.1 BioNTech SE Company Information
13.8.2 BioNTech SE Tumour Neoantigens Product Offered
13.8.3 BioNTech SE Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 BioNTech SE Main Business Overview
13.8.5 BioNTech SE Latest Developments
13.9 Lilly
13.9.1 Lilly Company Information
13.9.2 Lilly Tumour Neoantigens Product Offered
13.9.3 Lilly Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Lilly Main Business Overview
13.9.5 Lilly Latest Developments
13.10 Scicomvisuals
13.10.1 Scicomvisuals Company Information
13.10.2 Scicomvisuals Tumour Neoantigens Product Offered
13.10.3 Scicomvisuals Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Scicomvisuals Main Business Overview
13.10.5 Scicomvisuals Latest Developments
13.11 Moderna, Inc
13.11.1 Moderna, Inc Company Information
13.11.2 Moderna, Inc Tumour Neoantigens Product Offered
13.11.3 Moderna, Inc Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Moderna, Inc Main Business Overview
13.11.5 Moderna, Inc Latest Developments
13.12 F. Hoffmann-La Roche Ltd
13.12.1 F. Hoffmann-La Roche Ltd Company Information
13.12.2 F. Hoffmann-La Roche Ltd Tumour Neoantigens Product Offered
13.12.3 F. Hoffmann-La Roche Ltd Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.12.5 F. Hoffmann-La Roche Ltd Latest Developments
13.13 Merck KGaA
13.13.1 Merck KGaA Company Information
13.13.2 Merck KGaA Tumour Neoantigens Product Offered
13.13.3 Merck KGaA Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Merck KGaA Main Business Overview
13.13.5 Merck KGaA Latest Developments
13.14 Sun Pharmaceutical Industries Ltd
13.14.1 Sun Pharmaceutical Industries Ltd Company Information
13.14.2 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product Offered
13.14.3 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Sun Pharmaceutical Industries Ltd Main Business Overview
13.14.5 Sun Pharmaceutical Industries Ltd Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Tumour Neoantigens Annual Sales 2017-2028
2.1.2 World Current & Future Analysis for Tumour Neoantigens by Geographic Region, 2017, 2022 & 2028
2.1.3 World Current & Future Analysis for Tumour Neoantigens by Country/Region, 2017, 2022 & 2028
2.2 Tumour Neoantigens Segment by Type
2.2.1 Common Neoantigens
2.2.2 Individualized Neoantigens
2.3 Tumour Neoantigens Sales by Type
2.3.1 Global Tumour Neoantigens Sales Market Share by Type (2017-2022)
2.3.2 Global Tumour Neoantigens Revenue and Market Share by Type (2017-2022)
2.3.3 Global Tumour Neoantigens Sale Price by Type (2017-2022)
2.4 Tumour Neoantigens Segment by Application
2.4.1 T Cell Adoptive Therapy
2.4.2 DC Therapy
2.4.3 Therapeutic Vaccines
2.4.4 Other
2.5 Tumour Neoantigens Sales by Application
2.5.1 Global Tumour Neoantigens Sale Market Share by Application (2017-2022)
2.5.2 Global Tumour Neoantigens Revenue and Market Share by Application (2017-2022)
2.5.3 Global Tumour Neoantigens Sale Price by Application (2017-2022)
3 GLOBAL TUMOUR NEOANTIGENS BY COMPANY
3.1 Global Tumour Neoantigens Breakdown Data by Company
3.1.1 Global Tumour Neoantigens Annual Sales by Company (2020-2022)
3.1.2 Global Tumour Neoantigens Sales Market Share by Company (2020-2022)
3.2 Global Tumour Neoantigens Annual Revenue by Company (2020-2022)
3.2.1 Global Tumour Neoantigens Revenue by Company (2020-2022)
3.2.2 Global Tumour Neoantigens Revenue Market Share by Company (2020-2022)
3.3 Global Tumour Neoantigens Sale Price by Company
3.4 Key Manufacturers Tumour Neoantigens Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Tumour Neoantigens Product Location Distribution
3.4.2 Players Tumour Neoantigens Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 WORLD HISTORIC REVIEW FOR TUMOUR NEOANTIGENS BY GEOGRAPHIC REGION
4.1 World Historic Tumour Neoantigens Market Size by Geographic Region (2017-2022)
4.1.1 Global Tumour Neoantigens Annual Sales by Geographic Region (2017-2022)
4.1.2 Global Tumour Neoantigens Annual Revenue by Geographic Region
4.2 World Historic Tumour Neoantigens Market Size by Country/Region (2017-2022)
4.2.1 Global Tumour Neoantigens Annual Sales by Country/Region (2017-2022)
4.2.2 Global Tumour Neoantigens Annual Revenue by Country/Region
4.3 Americas Tumour Neoantigens Sales Growth
4.4 APAC Tumour Neoantigens Sales Growth
4.5 Europe Tumour Neoantigens Sales Growth
4.6 Middle East & Africa Tumour Neoantigens Sales Growth
5 AMERICAS
5.1 Americas Tumour Neoantigens Sales by Country
5.1.1 Americas Tumour Neoantigens Sales by Country (2017-2022)
5.1.2 Americas Tumour Neoantigens Revenue by Country (2017-2022)
5.2 Americas Tumour Neoantigens Sales by Type
5.3 Americas Tumour Neoantigens Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Tumour Neoantigens Sales by Region
6.1.1 APAC Tumour Neoantigens Sales by Region (2017-2022)
6.1.2 APAC Tumour Neoantigens Revenue by Region (2017-2022)
6.2 APAC Tumour Neoantigens Sales by Type
6.3 APAC Tumour Neoantigens Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Tumour Neoantigens by Country
7.1.1 Europe Tumour Neoantigens Sales by Country (2017-2022)
7.1.2 Europe Tumour Neoantigens Revenue by Country (2017-2022)
7.2 Europe Tumour Neoantigens Sales by Type
7.3 Europe Tumour Neoantigens Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Tumour Neoantigens by Country
8.1.1 Middle East & Africa Tumour Neoantigens Sales by Country (2017-2022)
8.1.2 Middle East & Africa Tumour Neoantigens Revenue by Country (2017-2022)
8.2 Middle East & Africa Tumour Neoantigens Sales by Type
8.3 Middle East & Africa Tumour Neoantigens Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Tumour Neoantigens
10.3 Manufacturing Process Analysis of Tumour Neoantigens
10.4 Industry Chain Structure of Tumour Neoantigens
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Tumour Neoantigens Distributors
11.3 Tumour Neoantigens Customer
12 WORLD FORECAST REVIEW FOR TUMOUR NEOANTIGENS BY GEOGRAPHIC REGION
12.1 Global Tumour Neoantigens Market Size Forecast by Region
12.1.1 Global Tumour Neoantigens Forecast by Region (2023-2028)
12.1.2 Global Tumour Neoantigens Annual Revenue Forecast by Region (2023-2028)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Tumour Neoantigens Forecast by Type
12.7 Global Tumour Neoantigens Forecast by Application
13 KEY PLAYERS ANALYSIS
13.1 Achilles Therapeutics plc
13.1.1 Achilles Therapeutics plc Company Information
13.1.2 Achilles Therapeutics plc Tumour Neoantigens Product Offered
13.1.3 Achilles Therapeutics plc Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.1.4 Achilles Therapeutics plc Main Business Overview
13.1.5 Achilles Therapeutics plc Latest Developments
13.2 Advaxis Immunotherapies
13.2.1 Advaxis Immunotherapies Company Information
13.2.2 Advaxis Immunotherapies Tumour Neoantigens Product Offered
13.2.3 Advaxis Immunotherapies Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.2.4 Advaxis Immunotherapies Main Business Overview
13.2.5 Advaxis Immunotherapies Latest Developments
13.3 Genocea
13.3.1 Genocea Company Information
13.3.2 Genocea Tumour Neoantigens Product Offered
13.3.3 Genocea Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.3.4 Genocea Main Business Overview
13.3.5 Genocea Latest Developments
13.4 Gradalis, Inc
13.4.1 Gradalis, Inc Company Information
13.4.2 Gradalis, Inc Tumour Neoantigens Product Offered
13.4.3 Gradalis, Inc Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.4.4 Gradalis, Inc Main Business Overview
13.4.5 Gradalis, Inc Latest Developments
13.5 Gritstone bio
13.5.1 Gritstone bio Company Information
13.5.2 Gritstone bio Tumour Neoantigens Product Offered
13.5.3 Gritstone bio Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.5.4 Gritstone bio Main Business Overview
13.5.5 Gritstone bio Latest Developments
13.6 Iovance Biotherapetics Inc
13.6.1 Iovance Biotherapetics Inc Company Information
13.6.2 Iovance Biotherapetics Inc Tumour Neoantigens Product Offered
13.6.3 Iovance Biotherapetics Inc Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.6.4 Iovance Biotherapetics Inc Main Business Overview
13.6.5 Iovance Biotherapetics Inc Latest Developments
13.7 Medigene AG
13.7.1 Medigene AG Company Information
13.7.2 Medigene AG Tumour Neoantigens Product Offered
13.7.3 Medigene AG Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.7.4 Medigene AG Main Business Overview
13.7.5 Medigene AG Latest Developments
13.8 BioNTech SE
13.8.1 BioNTech SE Company Information
13.8.2 BioNTech SE Tumour Neoantigens Product Offered
13.8.3 BioNTech SE Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.8.4 BioNTech SE Main Business Overview
13.8.5 BioNTech SE Latest Developments
13.9 Lilly
13.9.1 Lilly Company Information
13.9.2 Lilly Tumour Neoantigens Product Offered
13.9.3 Lilly Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.9.4 Lilly Main Business Overview
13.9.5 Lilly Latest Developments
13.10 Scicomvisuals
13.10.1 Scicomvisuals Company Information
13.10.2 Scicomvisuals Tumour Neoantigens Product Offered
13.10.3 Scicomvisuals Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.10.4 Scicomvisuals Main Business Overview
13.10.5 Scicomvisuals Latest Developments
13.11 Moderna, Inc
13.11.1 Moderna, Inc Company Information
13.11.2 Moderna, Inc Tumour Neoantigens Product Offered
13.11.3 Moderna, Inc Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.11.4 Moderna, Inc Main Business Overview
13.11.5 Moderna, Inc Latest Developments
13.12 F. Hoffmann-La Roche Ltd
13.12.1 F. Hoffmann-La Roche Ltd Company Information
13.12.2 F. Hoffmann-La Roche Ltd Tumour Neoantigens Product Offered
13.12.3 F. Hoffmann-La Roche Ltd Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.12.4 F. Hoffmann-La Roche Ltd Main Business Overview
13.12.5 F. Hoffmann-La Roche Ltd Latest Developments
13.13 Merck KGaA
13.13.1 Merck KGaA Company Information
13.13.2 Merck KGaA Tumour Neoantigens Product Offered
13.13.3 Merck KGaA Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.13.4 Merck KGaA Main Business Overview
13.13.5 Merck KGaA Latest Developments
13.14 Sun Pharmaceutical Industries Ltd
13.14.1 Sun Pharmaceutical Industries Ltd Company Information
13.14.2 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product Offered
13.14.3 Sun Pharmaceutical Industries Ltd Tumour Neoantigens Sales, Revenue, Price and Gross Margin (2020-2022)
13.14.4 Sun Pharmaceutical Industries Ltd Main Business Overview
13.14.5 Sun Pharmaceutical Industries Ltd Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Tumour Neoantigens Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Tumour Neoantigens Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Common Neoantigens
Table 4. Major Players of Individualized Neoantigens
Table 5. Global Tumour Neoantigens Sales by Type (2017-2022) & (K Units)
Table 6. Global Tumour Neoantigens Sales Market Share by Type (2017-2022)
Table 7. Global Tumour Neoantigens Revenue by Type (2017-2022) & ($ million)
Table 8. Global Tumour Neoantigens Revenue Market Share by Type (2017-2022)
Table 9. Global Tumour Neoantigens Sale Price by Type (2017-2022) & (US$/Unit)
Table 10. Global Tumour Neoantigens Sales by Application (2017-2022) & (K Units)
Table 11. Global Tumour Neoantigens Sales Market Share by Application (2017-2022)
Table 12. Global Tumour Neoantigens Revenue by Application (2017-2022)
Table 13. Global Tumour Neoantigens Revenue Market Share by Application (2017-2022)
Table 14. Global Tumour Neoantigens Sale Price by Application (2017-2022) & (US$/Unit)
Table 15. Global Tumour Neoantigens Sales by Company (2020-2022) & (K Units)
Table 16. Global Tumour Neoantigens Sales Market Share by Company (2020-2022)
Table 17. Global Tumour Neoantigens Revenue by Company (2020-2022) ($ Millions)
Table 18. Global Tumour Neoantigens Revenue Market Share by Company (2020-2022)
Table 19. Global Tumour Neoantigens Sale Price by Company (2020-2022) & (US$/Unit)
Table 20. Key Manufacturers Tumour Neoantigens Producing Area Distribution and Sales Area
Table 21. Players Tumour Neoantigens Products Offered
Table 22. Tumour Neoantigens Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Tumour Neoantigens Sales by Geographic Region (2017-2022) & (K Units)
Table 26. Global Tumour Neoantigens Sales Market Share Geographic Region (2017-2022)
Table 27. Global Tumour Neoantigens Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global Tumour Neoantigens Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global Tumour Neoantigens Sales by Country/Region (2017-2022) & (K Units)
Table 30. Global Tumour Neoantigens Sales Market Share by Country/Region (2017-2022)
Table 31. Global Tumour Neoantigens Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global Tumour Neoantigens Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas Tumour Neoantigens Sales by Country (2017-2022) & (K Units)
Table 34. Americas Tumour Neoantigens Sales Market Share by Country (2017-2022)
Table 35. Americas Tumour Neoantigens Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas Tumour Neoantigens Revenue Market Share by Country (2017-2022)
Table 37. Americas Tumour Neoantigens Sales by Type (2017-2022) & (K Units)
Table 38. Americas Tumour Neoantigens Sales Market Share by Type (2017-2022)
Table 39. Americas Tumour Neoantigens Sales by Application (2017-2022) & (K Units)
Table 40. Americas Tumour Neoantigens Sales Market Share by Application (2017-2022)
Table 41. APAC Tumour Neoantigens Sales by Region (2017-2022) & (K Units)
Table 42. APAC Tumour Neoantigens Sales Market Share by Region (2017-2022)
Table 43. APAC Tumour Neoantigens Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC Tumour Neoantigens Revenue Market Share by Region (2017-2022)
Table 45. APAC Tumour Neoantigens Sales by Type (2017-2022) & (K Units)
Table 46. APAC Tumour Neoantigens Sales Market Share by Type (2017-2022)
Table 47. APAC Tumour Neoantigens Sales by Application (2017-2022) & (K Units)
Table 48. APAC Tumour Neoantigens Sales Market Share by Application (2017-2022)
Table 49. Europe Tumour Neoantigens Sales by Country (2017-2022) & (K Units)
Table 50. Europe Tumour Neoantigens Sales Market Share by Country (2017-2022)
Table 51. Europe Tumour Neoantigens Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe Tumour Neoantigens Revenue Market Share by Country (2017-2022)
Table 53. Europe Tumour Neoantigens Sales by Type (2017-2022) & (K Units)
Table 54. Europe Tumour Neoantigens Sales Market Share by Type (2017-2022)
Table 55. Europe Tumour Neoantigens Sales by Application (2017-2022) & (K Units)
Table 56. Europe Tumour Neoantigens Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa Tumour Neoantigens Sales by Country (2017-2022) & (K Units)
Table 58. Middle East & Africa Tumour Neoantigens Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa Tumour Neoantigens Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa Tumour Neoantigens Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa Tumour Neoantigens Sales by Type (2017-2022) & (K Units)
Table 62. Middle East & Africa Tumour Neoantigens Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa Tumour Neoantigens Sales by Application (2017-2022) & (K Units)
Table 64. Middle East & Africa Tumour Neoantigens Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of Tumour Neoantigens
Table 66. Key Market Challenges & Risks of Tumour Neoantigens
Table 67. Key Industry Trends of Tumour Neoantigens
Table 68. Tumour Neoantigens Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Tumour Neoantigens Distributors List
Table 71. Tumour Neoantigens Customer List
Table 72. Global Tumour Neoantigens Sales Forecast by Region (2023-2028) & (K Units)
Table 73. Global Tumour Neoantigens Sales Market Forecast by Region
Table 74. Global Tumour Neoantigens Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global Tumour Neoantigens Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas Tumour Neoantigens Sales Forecast by Country (2023-2028) & (K Units)
Table 77. Americas Tumour Neoantigens Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC Tumour Neoantigens Sales Forecast by Region (2023-2028) & (K Units)
Table 79. APAC Tumour Neoantigens Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe Tumour Neoantigens Sales Forecast by Country (2023-2028) & (K Units)
Table 81. Europe Tumour Neoantigens Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa Tumour Neoantigens Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Middle East & Africa Tumour Neoantigens Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global Tumour Neoantigens Sales Forecast by Type (2023-2028) & (K Units)
Table 85. Global Tumour Neoantigens Sales Market Share Forecast by Type (2023-2028)
Table 86. Global Tumour Neoantigens Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global Tumour Neoantigens Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global Tumour Neoantigens Sales Forecast by Application (2023-2028) & (K Units)
Table 89. Global Tumour Neoantigens Sales Market Share Forecast by Application (2023-2028)
Table 90. Global Tumour Neoantigens Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global Tumour Neoantigens Revenue Market Share Forecast by Application (2023-2028)
Table 92. Achilles Therapeutics plc Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 93. Achilles Therapeutics plc Tumour Neoantigens Product Offered
Table 94. Achilles Therapeutics plc Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 95. Achilles Therapeutics plc Main Business
Table 96. Achilles Therapeutics plc Latest Developments
Table 97. Advaxis Immunotherapies Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 98. Advaxis Immunotherapies Tumour Neoantigens Product Offered
Table 99. Advaxis Immunotherapies Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 100. Advaxis Immunotherapies Main Business
Table 101. Advaxis Immunotherapies Latest Developments
Table 102. Genocea Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 103. Genocea Tumour Neoantigens Product Offered
Table 104. Genocea Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 105. Genocea Main Business
Table 106. Genocea Latest Developments
Table 107. Gradalis, Inc Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 108. Gradalis, Inc Tumour Neoantigens Product Offered
Table 109. Gradalis, Inc Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 110. Gradalis, Inc Main Business
Table 111. Gradalis, Inc Latest Developments
Table 112. Gritstone bio Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 113. Gritstone bio Tumour Neoantigens Product Offered
Table 114. Gritstone bio Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 115. Gritstone bio Main Business
Table 116. Gritstone bio Latest Developments
Table 117. Iovance Biotherapetics Inc Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 118. Iovance Biotherapetics Inc Tumour Neoantigens Product Offered
Table 119. Iovance Biotherapetics Inc Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 120. Iovance Biotherapetics Inc Main Business
Table 121. Iovance Biotherapetics Inc Latest Developments
Table 122. Medigene AG Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 123. Medigene AG Tumour Neoantigens Product Offered
Table 124. Medigene AG Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 125. Medigene AG Main Business
Table 126. Medigene AG Latest Developments
Table 127. BioNTech SE Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 128. BioNTech SE Tumour Neoantigens Product Offered
Table 129. BioNTech SE Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 130. BioNTech SE Main Business
Table 131. BioNTech SE Latest Developments
Table 132. Lilly Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 133. Lilly Tumour Neoantigens Product Offered
Table 134. Lilly Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 135. Lilly Main Business
Table 136. Lilly Latest Developments
Table 137. Scicomvisuals Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 138. Scicomvisuals Tumour Neoantigens Product Offered
Table 139. Scicomvisuals Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 140. Scicomvisuals Main Business
Table 141. Scicomvisuals Latest Developments
Table 142. Moderna, Inc Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 143. Moderna, Inc Tumour Neoantigens Product Offered
Table 144. Moderna, Inc Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 145. Moderna, Inc Main Business
Table 146. Moderna, Inc Latest Developments
Table 147. F. Hoffmann-La Roche Ltd Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 148. F. Hoffmann-La Roche Ltd Tumour Neoantigens Product Offered
Table 149. F. Hoffmann-La Roche Ltd Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 150. F. Hoffmann-La Roche Ltd Main Business
Table 151. F. Hoffmann-La Roche Ltd Latest Developments
Table 152. Merck KGaA Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 153. Merck KGaA Tumour Neoantigens Product Offered
Table 154. Merck KGaA Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 155. Merck KGaA Main Business
Table 156. Merck KGaA Latest Developments
Table 157. Sun Pharmaceutical Industries Ltd Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 158. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product Offered
Table 159. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 160. Sun Pharmaceutical Industries Ltd Main Business
Table 161. Sun Pharmaceutical Industries Ltd Latest Developments
Table 1. Tumour Neoantigens Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
Table 2. Tumour Neoantigens Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
Table 3. Major Players of Common Neoantigens
Table 4. Major Players of Individualized Neoantigens
Table 5. Global Tumour Neoantigens Sales by Type (2017-2022) & (K Units)
Table 6. Global Tumour Neoantigens Sales Market Share by Type (2017-2022)
Table 7. Global Tumour Neoantigens Revenue by Type (2017-2022) & ($ million)
Table 8. Global Tumour Neoantigens Revenue Market Share by Type (2017-2022)
Table 9. Global Tumour Neoantigens Sale Price by Type (2017-2022) & (US$/Unit)
Table 10. Global Tumour Neoantigens Sales by Application (2017-2022) & (K Units)
Table 11. Global Tumour Neoantigens Sales Market Share by Application (2017-2022)
Table 12. Global Tumour Neoantigens Revenue by Application (2017-2022)
Table 13. Global Tumour Neoantigens Revenue Market Share by Application (2017-2022)
Table 14. Global Tumour Neoantigens Sale Price by Application (2017-2022) & (US$/Unit)
Table 15. Global Tumour Neoantigens Sales by Company (2020-2022) & (K Units)
Table 16. Global Tumour Neoantigens Sales Market Share by Company (2020-2022)
Table 17. Global Tumour Neoantigens Revenue by Company (2020-2022) ($ Millions)
Table 18. Global Tumour Neoantigens Revenue Market Share by Company (2020-2022)
Table 19. Global Tumour Neoantigens Sale Price by Company (2020-2022) & (US$/Unit)
Table 20. Key Manufacturers Tumour Neoantigens Producing Area Distribution and Sales Area
Table 21. Players Tumour Neoantigens Products Offered
Table 22. Tumour Neoantigens Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Tumour Neoantigens Sales by Geographic Region (2017-2022) & (K Units)
Table 26. Global Tumour Neoantigens Sales Market Share Geographic Region (2017-2022)
Table 27. Global Tumour Neoantigens Revenue by Geographic Region (2017-2022) & ($ millions)
Table 28. Global Tumour Neoantigens Revenue Market Share by Geographic Region (2017-2022)
Table 29. Global Tumour Neoantigens Sales by Country/Region (2017-2022) & (K Units)
Table 30. Global Tumour Neoantigens Sales Market Share by Country/Region (2017-2022)
Table 31. Global Tumour Neoantigens Revenue by Country/Region (2017-2022) & ($ millions)
Table 32. Global Tumour Neoantigens Revenue Market Share by Country/Region (2017-2022)
Table 33. Americas Tumour Neoantigens Sales by Country (2017-2022) & (K Units)
Table 34. Americas Tumour Neoantigens Sales Market Share by Country (2017-2022)
Table 35. Americas Tumour Neoantigens Revenue by Country (2017-2022) & ($ Millions)
Table 36. Americas Tumour Neoantigens Revenue Market Share by Country (2017-2022)
Table 37. Americas Tumour Neoantigens Sales by Type (2017-2022) & (K Units)
Table 38. Americas Tumour Neoantigens Sales Market Share by Type (2017-2022)
Table 39. Americas Tumour Neoantigens Sales by Application (2017-2022) & (K Units)
Table 40. Americas Tumour Neoantigens Sales Market Share by Application (2017-2022)
Table 41. APAC Tumour Neoantigens Sales by Region (2017-2022) & (K Units)
Table 42. APAC Tumour Neoantigens Sales Market Share by Region (2017-2022)
Table 43. APAC Tumour Neoantigens Revenue by Region (2017-2022) & ($ Millions)
Table 44. APAC Tumour Neoantigens Revenue Market Share by Region (2017-2022)
Table 45. APAC Tumour Neoantigens Sales by Type (2017-2022) & (K Units)
Table 46. APAC Tumour Neoantigens Sales Market Share by Type (2017-2022)
Table 47. APAC Tumour Neoantigens Sales by Application (2017-2022) & (K Units)
Table 48. APAC Tumour Neoantigens Sales Market Share by Application (2017-2022)
Table 49. Europe Tumour Neoantigens Sales by Country (2017-2022) & (K Units)
Table 50. Europe Tumour Neoantigens Sales Market Share by Country (2017-2022)
Table 51. Europe Tumour Neoantigens Revenue by Country (2017-2022) & ($ Millions)
Table 52. Europe Tumour Neoantigens Revenue Market Share by Country (2017-2022)
Table 53. Europe Tumour Neoantigens Sales by Type (2017-2022) & (K Units)
Table 54. Europe Tumour Neoantigens Sales Market Share by Type (2017-2022)
Table 55. Europe Tumour Neoantigens Sales by Application (2017-2022) & (K Units)
Table 56. Europe Tumour Neoantigens Sales Market Share by Application (2017-2022)
Table 57. Middle East & Africa Tumour Neoantigens Sales by Country (2017-2022) & (K Units)
Table 58. Middle East & Africa Tumour Neoantigens Sales Market Share by Country (2017-2022)
Table 59. Middle East & Africa Tumour Neoantigens Revenue by Country (2017-2022) & ($ Millions)
Table 60. Middle East & Africa Tumour Neoantigens Revenue Market Share by Country (2017-2022)
Table 61. Middle East & Africa Tumour Neoantigens Sales by Type (2017-2022) & (K Units)
Table 62. Middle East & Africa Tumour Neoantigens Sales Market Share by Type (2017-2022)
Table 63. Middle East & Africa Tumour Neoantigens Sales by Application (2017-2022) & (K Units)
Table 64. Middle East & Africa Tumour Neoantigens Sales Market Share by Application (2017-2022)
Table 65. Key Market Drivers & Growth Opportunities of Tumour Neoantigens
Table 66. Key Market Challenges & Risks of Tumour Neoantigens
Table 67. Key Industry Trends of Tumour Neoantigens
Table 68. Tumour Neoantigens Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Tumour Neoantigens Distributors List
Table 71. Tumour Neoantigens Customer List
Table 72. Global Tumour Neoantigens Sales Forecast by Region (2023-2028) & (K Units)
Table 73. Global Tumour Neoantigens Sales Market Forecast by Region
Table 74. Global Tumour Neoantigens Revenue Forecast by Region (2023-2028) & ($ millions)
Table 75. Global Tumour Neoantigens Revenue Market Share Forecast by Region (2023-2028)
Table 76. Americas Tumour Neoantigens Sales Forecast by Country (2023-2028) & (K Units)
Table 77. Americas Tumour Neoantigens Revenue Forecast by Country (2023-2028) & ($ millions)
Table 78. APAC Tumour Neoantigens Sales Forecast by Region (2023-2028) & (K Units)
Table 79. APAC Tumour Neoantigens Revenue Forecast by Region (2023-2028) & ($ millions)
Table 80. Europe Tumour Neoantigens Sales Forecast by Country (2023-2028) & (K Units)
Table 81. Europe Tumour Neoantigens Revenue Forecast by Country (2023-2028) & ($ millions)
Table 82. Middle East & Africa Tumour Neoantigens Sales Forecast by Country (2023-2028) & (K Units)
Table 83. Middle East & Africa Tumour Neoantigens Revenue Forecast by Country (2023-2028) & ($ millions)
Table 84. Global Tumour Neoantigens Sales Forecast by Type (2023-2028) & (K Units)
Table 85. Global Tumour Neoantigens Sales Market Share Forecast by Type (2023-2028)
Table 86. Global Tumour Neoantigens Revenue Forecast by Type (2023-2028) & ($ Millions)
Table 87. Global Tumour Neoantigens Revenue Market Share Forecast by Type (2023-2028)
Table 88. Global Tumour Neoantigens Sales Forecast by Application (2023-2028) & (K Units)
Table 89. Global Tumour Neoantigens Sales Market Share Forecast by Application (2023-2028)
Table 90. Global Tumour Neoantigens Revenue Forecast by Application (2023-2028) & ($ Millions)
Table 91. Global Tumour Neoantigens Revenue Market Share Forecast by Application (2023-2028)
Table 92. Achilles Therapeutics plc Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 93. Achilles Therapeutics plc Tumour Neoantigens Product Offered
Table 94. Achilles Therapeutics plc Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 95. Achilles Therapeutics plc Main Business
Table 96. Achilles Therapeutics plc Latest Developments
Table 97. Advaxis Immunotherapies Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 98. Advaxis Immunotherapies Tumour Neoantigens Product Offered
Table 99. Advaxis Immunotherapies Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 100. Advaxis Immunotherapies Main Business
Table 101. Advaxis Immunotherapies Latest Developments
Table 102. Genocea Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 103. Genocea Tumour Neoantigens Product Offered
Table 104. Genocea Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 105. Genocea Main Business
Table 106. Genocea Latest Developments
Table 107. Gradalis, Inc Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 108. Gradalis, Inc Tumour Neoantigens Product Offered
Table 109. Gradalis, Inc Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 110. Gradalis, Inc Main Business
Table 111. Gradalis, Inc Latest Developments
Table 112. Gritstone bio Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 113. Gritstone bio Tumour Neoantigens Product Offered
Table 114. Gritstone bio Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 115. Gritstone bio Main Business
Table 116. Gritstone bio Latest Developments
Table 117. Iovance Biotherapetics Inc Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 118. Iovance Biotherapetics Inc Tumour Neoantigens Product Offered
Table 119. Iovance Biotherapetics Inc Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 120. Iovance Biotherapetics Inc Main Business
Table 121. Iovance Biotherapetics Inc Latest Developments
Table 122. Medigene AG Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 123. Medigene AG Tumour Neoantigens Product Offered
Table 124. Medigene AG Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 125. Medigene AG Main Business
Table 126. Medigene AG Latest Developments
Table 127. BioNTech SE Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 128. BioNTech SE Tumour Neoantigens Product Offered
Table 129. BioNTech SE Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 130. BioNTech SE Main Business
Table 131. BioNTech SE Latest Developments
Table 132. Lilly Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 133. Lilly Tumour Neoantigens Product Offered
Table 134. Lilly Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 135. Lilly Main Business
Table 136. Lilly Latest Developments
Table 137. Scicomvisuals Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 138. Scicomvisuals Tumour Neoantigens Product Offered
Table 139. Scicomvisuals Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 140. Scicomvisuals Main Business
Table 141. Scicomvisuals Latest Developments
Table 142. Moderna, Inc Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 143. Moderna, Inc Tumour Neoantigens Product Offered
Table 144. Moderna, Inc Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 145. Moderna, Inc Main Business
Table 146. Moderna, Inc Latest Developments
Table 147. F. Hoffmann-La Roche Ltd Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 148. F. Hoffmann-La Roche Ltd Tumour Neoantigens Product Offered
Table 149. F. Hoffmann-La Roche Ltd Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 150. F. Hoffmann-La Roche Ltd Main Business
Table 151. F. Hoffmann-La Roche Ltd Latest Developments
Table 152. Merck KGaA Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 153. Merck KGaA Tumour Neoantigens Product Offered
Table 154. Merck KGaA Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 155. Merck KGaA Main Business
Table 156. Merck KGaA Latest Developments
Table 157. Sun Pharmaceutical Industries Ltd Basic Information, Tumour Neoantigens Manufacturing Base, Sales Area and Its Competitors
Table 158. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Product Offered
Table 159. Sun Pharmaceutical Industries Ltd Tumour Neoantigens Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
Table 160. Sun Pharmaceutical Industries Ltd Main Business
Table 161. Sun Pharmaceutical Industries Ltd Latest Developments
LIST OF FIGURES
Figure 1. Picture of Tumour Neoantigens
Figure 2. Tumour Neoantigens Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Tumour Neoantigens Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Tumour Neoantigens Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Tumour Neoantigens Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Common Neoantigens
Figure 10. Product Picture of Individualized Neoantigens
Figure 11. Global Tumour Neoantigens Sales Market Share by Type in 2021
Figure 12. Global Tumour Neoantigens Revenue Market Share by Type (2017-2022)
Figure 13. Tumour Neoantigens Consumed in T Cell Adoptive Therapy
Figure 14. Global Tumour Neoantigens Market: T Cell Adoptive Therapy (2017-2022) & (K Units)
Figure 15. Tumour Neoantigens Consumed in DC Therapy
Figure 16. Global Tumour Neoantigens Market: DC Therapy (2017-2022) & (K Units)
Figure 17. Tumour Neoantigens Consumed in Therapeutic Vaccines
Figure 18. Global Tumour Neoantigens Market: Therapeutic Vaccines (2017-2022) & (K Units)
Figure 19. Tumour Neoantigens Consumed in Other
Figure 20. Global Tumour Neoantigens Market: Other (2017-2022) & (K Units)
Figure 21. Global Tumour Neoantigens Sales Market Share by Application (2017-2022)
Figure 22. Global Tumour Neoantigens Revenue Market Share by Application in 2021
Figure 23. Tumour Neoantigens Revenue Market by Company in 2021 ($ Million)
Figure 24. Global Tumour Neoantigens Revenue Market Share by Company in 2021
Figure 25. Global Tumour Neoantigens Sales Market Share by Geographic Region (2017-2022)
Figure 26. Global Tumour Neoantigens Revenue Market Share by Geographic Region in 2021
Figure 27. Global Tumour Neoantigens Sales Market Share by Region (2017-2022)
Figure 28. Global Tumour Neoantigens Revenue Market Share by Country/Region in 2021
Figure 29. Americas Tumour Neoantigens Sales 2017-2022 (K Units)
Figure 30. Americas Tumour Neoantigens Revenue 2017-2022 ($ Millions)
Figure 31. APAC Tumour Neoantigens Sales 2017-2022 (K Units)
Figure 32. APAC Tumour Neoantigens Revenue 2017-2022 ($ Millions)
Figure 33. Europe Tumour Neoantigens Sales 2017-2022 (K Units)
Figure 34. Europe Tumour Neoantigens Revenue 2017-2022 ($ Millions)
Figure 35. Middle East & Africa Tumour Neoantigens Sales 2017-2022 (K Units)
Figure 36. Middle East & Africa Tumour Neoantigens Revenue 2017-2022 ($ Millions)
Figure 37. Americas Tumour Neoantigens Sales Market Share by Country in 2021
Figure 38. Americas Tumour Neoantigens Revenue Market Share by Country in 2021
Figure 39. United States Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 40. Canada Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 41. Mexico Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 42. Brazil Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 43. APAC Tumour Neoantigens Sales Market Share by Region in 2021
Figure 44. APAC Tumour Neoantigens Revenue Market Share by Regions in 2021
Figure 45. China Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 46. Japan Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 47. South Korea Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 48. Southeast Asia Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 49. India Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 50. Australia Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 51. Europe Tumour Neoantigens Sales Market Share by Country in 2021
Figure 52. Europe Tumour Neoantigens Revenue Market Share by Country in 2021
Figure 53. Germany Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 54. France Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 55. UK Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 56. Italy Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 57. Russia Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 58. Middle East & Africa Tumour Neoantigens Sales Market Share by Country in 2021
Figure 59. Middle East & Africa Tumour Neoantigens Revenue Market Share by Country in 2021
Figure 60. Egypt Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 61. South Africa Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 62. Israel Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 63. Turkey Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 64. GCC Country Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 65. Manufacturing Cost Structure Analysis of Tumour Neoantigens in 2021
Figure 66. Manufacturing Process Analysis of Tumour Neoantigens
Figure 67. Industry Chain Structure of Tumour Neoantigens
Figure 68. Channels of Distribution
Figure 69. Distributors Profiles
Figure 1. Picture of Tumour Neoantigens
Figure 2. Tumour Neoantigens Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Tumour Neoantigens Sales Growth Rate 2017-2028 (K Units)
Figure 7. Global Tumour Neoantigens Revenue Growth Rate 2017-2028 ($ Millions)
Figure 8. Tumour Neoantigens Sales by Region (2021 & 2028) & ($ millions)
Figure 9. Product Picture of Common Neoantigens
Figure 10. Product Picture of Individualized Neoantigens
Figure 11. Global Tumour Neoantigens Sales Market Share by Type in 2021
Figure 12. Global Tumour Neoantigens Revenue Market Share by Type (2017-2022)
Figure 13. Tumour Neoantigens Consumed in T Cell Adoptive Therapy
Figure 14. Global Tumour Neoantigens Market: T Cell Adoptive Therapy (2017-2022) & (K Units)
Figure 15. Tumour Neoantigens Consumed in DC Therapy
Figure 16. Global Tumour Neoantigens Market: DC Therapy (2017-2022) & (K Units)
Figure 17. Tumour Neoantigens Consumed in Therapeutic Vaccines
Figure 18. Global Tumour Neoantigens Market: Therapeutic Vaccines (2017-2022) & (K Units)
Figure 19. Tumour Neoantigens Consumed in Other
Figure 20. Global Tumour Neoantigens Market: Other (2017-2022) & (K Units)
Figure 21. Global Tumour Neoantigens Sales Market Share by Application (2017-2022)
Figure 22. Global Tumour Neoantigens Revenue Market Share by Application in 2021
Figure 23. Tumour Neoantigens Revenue Market by Company in 2021 ($ Million)
Figure 24. Global Tumour Neoantigens Revenue Market Share by Company in 2021
Figure 25. Global Tumour Neoantigens Sales Market Share by Geographic Region (2017-2022)
Figure 26. Global Tumour Neoantigens Revenue Market Share by Geographic Region in 2021
Figure 27. Global Tumour Neoantigens Sales Market Share by Region (2017-2022)
Figure 28. Global Tumour Neoantigens Revenue Market Share by Country/Region in 2021
Figure 29. Americas Tumour Neoantigens Sales 2017-2022 (K Units)
Figure 30. Americas Tumour Neoantigens Revenue 2017-2022 ($ Millions)
Figure 31. APAC Tumour Neoantigens Sales 2017-2022 (K Units)
Figure 32. APAC Tumour Neoantigens Revenue 2017-2022 ($ Millions)
Figure 33. Europe Tumour Neoantigens Sales 2017-2022 (K Units)
Figure 34. Europe Tumour Neoantigens Revenue 2017-2022 ($ Millions)
Figure 35. Middle East & Africa Tumour Neoantigens Sales 2017-2022 (K Units)
Figure 36. Middle East & Africa Tumour Neoantigens Revenue 2017-2022 ($ Millions)
Figure 37. Americas Tumour Neoantigens Sales Market Share by Country in 2021
Figure 38. Americas Tumour Neoantigens Revenue Market Share by Country in 2021
Figure 39. United States Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 40. Canada Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 41. Mexico Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 42. Brazil Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 43. APAC Tumour Neoantigens Sales Market Share by Region in 2021
Figure 44. APAC Tumour Neoantigens Revenue Market Share by Regions in 2021
Figure 45. China Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 46. Japan Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 47. South Korea Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 48. Southeast Asia Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 49. India Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 50. Australia Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 51. Europe Tumour Neoantigens Sales Market Share by Country in 2021
Figure 52. Europe Tumour Neoantigens Revenue Market Share by Country in 2021
Figure 53. Germany Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 54. France Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 55. UK Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 56. Italy Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 57. Russia Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 58. Middle East & Africa Tumour Neoantigens Sales Market Share by Country in 2021
Figure 59. Middle East & Africa Tumour Neoantigens Revenue Market Share by Country in 2021
Figure 60. Egypt Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 61. South Africa Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 62. Israel Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 63. Turkey Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 64. GCC Country Tumour Neoantigens Revenue Growth 2017-2022 ($ Millions)
Figure 65. Manufacturing Cost Structure Analysis of Tumour Neoantigens in 2021
Figure 66. Manufacturing Process Analysis of Tumour Neoantigens
Figure 67. Industry Chain Structure of Tumour Neoantigens
Figure 68. Channels of Distribution
Figure 69. Distributors Profiles
